Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cytokinetics (CYTK)

Cytokinetics (CYTK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 546,509
  • Shares Outstanding, K 59,082
  • Annual Sales, $ 31,500 K
  • Annual Income, $ -106,290 K
  • 60-Month Beta 1.54
  • Price/Sales 15.74
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.50
  • Number of Estimates 2
  • High Estimate -0.50
  • Low Estimate -0.51
  • Prior Year -0.48
  • Growth Rate Est. (year over year) -4.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.72 +23.62%
on 11/08/19
12.44 -23.23%
on 11/01/19
-1.42 (-12.94%)
since 10/18/19
3-Month
7.72 +23.62%
on 11/08/19
14.94 -36.08%
on 09/06/19
-4.23 (-30.70%)
since 08/20/19
52-Week
5.75 +66.09%
on 03/07/19
14.94 -36.08%
on 09/06/19
+2.42 (+33.94%)
since 11/20/18

Most Recent Stories

More News
Cytokinetics Inc Rises 4.89% on Heavy Volume: Watch For Potential Pullback

Cytokinetics Inc (NASDAQ:CYTK) traded in a range yesterday that spanned from a low of $8.31 to a high of $8.90. Yesterday, the shares gained 4.9%, which took the trading range above the 3-day high of...

CYTK : 9.55 (+3.24%)
New Results From COSMIC-HF Presented at AHA 2019 Show Treatment of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral or Improved Measures of Diastolic Function

Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier announced that new results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure),...

AMGN : 225.51 (+0.45%)
CYTK : 9.55 (+3.24%)
Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at the American Heart Association Scientific Sessions 2019

Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating...

CYTK : 9.55 (+3.24%)
Cytokinetics Inc Falls 28.13% on Heavy Volume: Watch For Potential Rebound

Cytokinetics Inc (NASDAQ:CYTK) traded in a range yesterday that spanned from a low of $7.91 to a high of $8.22. Yesterday, the shares fell 28.1%, which took the trading range below the 3-day low of $8.62...

CYTK : 9.55 (+3.24%)
Cytokinetics Announces Pricing of Public Offering of Convertible Senior Notes

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it has agreed to sell an aggregate of $120.0 million principal amount of its 4.00% convertible senior notes due 2026, or the notes, in an...

CYTK : 9.55 (+3.24%)
Cytokinetics Announces Proposed Public Offering of Convertible Senior Notes

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it expects to sell, subject to market and other conditions, an aggregate of $100.0 million principal amount of its convertible senior notes...

CYTK : 9.55 (+3.24%)
Cytokinetics to Participate in the Credit Suisse 28th Annual Healthcare Conference

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Fady I. Malik, M.D., Ph.D., Executive Vice President, Research & Development, is scheduled to participate in the Credit Suisse 28 Annual Healthcare...

CYTK : 9.55 (+3.24%)
Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of 10.71% and -22.37%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

CYTK : 9.55 (+3.24%)
Cytokinetics: 3Q Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. (AP) _ Cytokinetics Inc. (CYTK) on Thursday reported a loss of $29.6 million in its third quarter.

CYTK : 9.55 (+3.24%)
Cytokinetics Reports Third Quarter 2019 Financial Results

Enrollment Completed in GALACTIC-HF with More than 8,200 Heart Failure Patients;

CYTK : 9.55 (+3.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More Share

Trade CYTK with:

Business Summary

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology...

See More

Key Turning Points

2nd Resistance Point 10.09
1st Resistance Point 9.82
Last Price 9.55
1st Support Level 9.21
2nd Support Level 8.87

See More

52-Week High 14.94
Fibonacci 61.8% 11.43
Fibonacci 50% 10.34
Last Price 9.55
Fibonacci 38.2% 9.26
52-Week Low 5.75

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar